D.E. Shaw & Co
STRO icon

D.E. Shaw & Co’s Sutro Biopharma STRO Stock Holding History

D.E. Shaw & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,804
Closed -$103K – 4704
2025
Q1 		$103K Buy
15,804
+36
+0.2% +$567 ﹤0.01% 4013
2024
Q4 		$290K Sell
15,768
-997
-6% -$30.4K ﹤0.01% 3910
2024
Q3 		$580K Buy
16,765
+3,898
+30% +$153K ﹤0.01% 3612
2024
Q2 		$377K Sell
12,867
-11,297
-47% -$447K ﹤0.01% 3779
2024
Q1 		$1.37M Buy
+24,164
New +$1.07M ﹤0.01% 2894
2023
Q3 		– Sell
-4,072
Closed -$189K – 4485
2023
Q2 		$189K Sell
4,072
-11,448
-74% -$570K ﹤0.01% 3753
2023
Q1 		$717K Sell
15,520
-12,039
-44% -$764K ﹤0.01% 3372
2022
Q4 		$2.23M Sell
27,559
-3,942
-13% -$274K ﹤0.01% 2850
2022
Q3 		$1.75M Buy
31,501
+5,561
+21% +$329K ﹤0.01% 3118
2022
Q2 		$1.35M Buy
+25,940
New +$1.45M ﹤0.01% 3414
2022
Q1 		– Sell
-3,066
Closed -$456K – 5922
2021
Q4 		$456K Sell
3,066
-673
-18% -$121K ﹤0.01% 4454
2021
Q3 		$706K Buy
3,739
+841
+29% +$160K ﹤0.01% 3861
2021
Q2 		$539K Sell
2,898
-1,363
-32% -$267K ﹤0.01% 4003
2021
Q1 		$970K Sell
4,261
-5,602
-57% -$1.33M ﹤0.01% 3139
2020
Q4 		$2.14M Buy
+9,863
New +$1.63M ﹤0.01% 2512

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

D.E. Shaw & Co's STRO Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 15,804 shares — an estimated $103K sold.

D.E. Shaw & Co first reported a position in STRO in Q4 2020 and held it in 15 quarters. The position peaked at $2.23M in Q4 2022. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,804 Sutro Biopharma shares in Q2 2025, an estimated $103K.
  • D.E. Shaw & Co first reported a position in Sutro Biopharma in Q4 2020 and held it in 15 quarters.
  • D.E. Shaw & Co's Sutro Biopharma position peaked at $2.23M in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.